Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 131 - PubMed (original) (raw)
Multicenter Study
doi: 10.1089/mdr.2014.0261. Epub 2015 Mar 10.
Affiliations
- PMID: 25756854
- DOI: 10.1089/mdr.2014.0261
Multicenter Study
Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 131
Sun Young Cho et al. Microb Drug Resist. 2015 Aug.
Abstract
Despite the remarkable emergence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli sequence type 131 (ST131), the clinical features and outcomes of infections caused by ST131 remain poorly described. From 2011 to 2012, we collected ESBL-producing E. coli isolates from patients with bloodstream infections in 13 hospitals in Korea and compared clinical characteristics and outcomes between ST131 and non-ST131 clones. Of the 110 ESBL-producing isolates, the most common ST was ST131 (30.9%). Multivariate analysis showed that recent operation was the only variable associated with the ST131 clone; other comorbid conditions and clinical features were similar between ST131 and non-ST131 clones. CTX-M-14 and CTX-M-15 were the predominant types of ESBLs, and CTX-M-15 was significantly associated with ST131. The rate of nonsusceptibility to ciprofloxacin was higher in ST131 than in non-ST131 clones (94.1% vs. 75.0%). No significant differences in 30-day mortality rates were found between ST131 and non-ST131 clones. Multivariate analysis revealed that older age (odds ratio [OR]=5.39, 95% confidence interval [CI] 1.22-23.89; p=0.027), nosocomial infection (OR=4.81, 95% CI 1.15-20.15; p=0.032), and higher Pitt bacteremia score (OR=7.26, 95% CI 1.41-37.42; p=0.018) were independent risk factors for 30-day mortality. The ESBL-producing E. coli ST131 clone has emerged and disseminated in Korea. Our findings reveal similarities in clinical and demographic characteristics between ST131 and non-ST131 clones. Although a more resistant profile has been detected in ST131, patients with the ST131 clone did not exhibit a higher mortality rate.
Similar articles
- Bacteremia caused by extended-spectrum-β-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality.
Chung HC, Lai CH, Lin JN, Huang CK, Liang SH, Chen WF, Shih YC, Lin HH, Wang JL. Chung HC, et al. Antimicrob Agents Chemother. 2012 Feb;56(2):618-22. doi: 10.1128/AAC.05753-11. Epub 2011 Nov 28. Antimicrob Agents Chemother. 2012. PMID: 22123694 Free PMC article. - Prevalence of CTX-M extended-spectrum beta-lactamases and sequence type 131 in Korean blood, urine, and rectal Escherichia coli isolates.
Graham SE, Zhang L, Ali I, Cho YK, Ismail MD, Carlson HA, Foxman B. Graham SE, et al. Infect Genet Evol. 2016 Jul;41:292-295. doi: 10.1016/j.meegid.2016.04.020. Epub 2016 Apr 19. Infect Genet Evol. 2016. PMID: 27101781 - Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer.
Ha YE, Kang CI, Cha MK, Park SY, Wi YM, Chung DR, Peck KR, Lee NY, Song JH. Ha YE, et al. Int J Antimicrob Agents. 2013 Nov;42(5):403-9. doi: 10.1016/j.ijantimicag.2013.07.018. Epub 2013 Sep 7. Int J Antimicrob Agents. 2013. PMID: 24071027 - Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4.
Peirano G, Pitout JD. Peirano G, et al. Int J Antimicrob Agents. 2010 Apr;35(4):316-21. doi: 10.1016/j.ijantimicag.2009.11.003. Epub 2010 Jan 13. Int J Antimicrob Agents. 2010. PMID: 20060273 Review. - Preliminary insights into the occurrence of similar clones of extended-spectrum beta-lactamase-producing bacteria in humans, animals and the environment in Tanzania: A systematic review and meta-analysis between 2005 and 2016.
Seni J, Moremi N, Matee M, van der Meer F, DeVinney R, Mshana SE, D Pitout JD. Seni J, et al. Zoonoses Public Health. 2018 Feb;65(1):1-10. doi: 10.1111/zph.12387. Epub 2017 Aug 22. Zoonoses Public Health. 2018. PMID: 28834351 Review.
Cited by
- Escherichia coli ST131 Associated with Increased Mortality in Bloodstream Infections from Urinary Tract Source.
Brumwell A, Sutton G, Lantos PM, Hoffman K, Ruffin F, Brinkac L, Clarke TH, Adams MD, Fowler VG Jr, Fouts DE, Thaden JT. Brumwell A, et al. J Clin Microbiol. 2023 Jul 20;61(7):e0019923. doi: 10.1128/jcm.00199-23. Epub 2023 Jun 20. J Clin Microbiol. 2023. PMID: 37338371 Free PMC article. - From Pathophysiological Hypotheses to Case-Control Study Design: Resistance from Antibiotic Exposure in Community-Onset Infections.
Abbara S, Guillemot D, Brun-Buisson C, Watier L. Abbara S, et al. Antibiotics (Basel). 2022 Feb 4;11(2):201. doi: 10.3390/antibiotics11020201. Antibiotics (Basel). 2022. PMID: 35203803 Free PMC article. - [Bloodstream infections with Escherichia coli O16-ST131 and O25b-ST131: molecular epidemiology, phylogenetic analysis and antimicrobial resistance].
Zhong Y, Zhang X, Liu W, Yang F, Yan Q, Liu Q, Li Y, Li H, Zou M. Zhong Y, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2018 Dec 30;38(12):1521-1526. doi: 10.12122/j.issn.1673-4254.2018.12.20. Nan Fang Yi Ke Da Xue Xue Bao. 2018. PMID: 30613024 Free PMC article. Chinese. - Predictors of mortality from extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia.
Namikawa H, Imoto W, Yamada K, Tochino Y, Kaneko Y, Kakeya H, Shuto T. Namikawa H, et al. Emerg Microbes Infect. 2023 Dec;12(1):2217951. doi: 10.1080/22221751.2023.2217951. Emerg Microbes Infect. 2023. PMID: 37219067 Free PMC article. Review. - Uropathogenic Escherichia coli ST131 in urinary tract infections in children.
Yun KW, Lee MK, Kim W, Lim IS. Yun KW, et al. Korean J Pediatr. 2017 Jul;60(7):221-226. doi: 10.3345/kjp.2017.60.7.221. Epub 2017 Jul 31. Korean J Pediatr. 2017. PMID: 28861113 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical